{
"indication": {
"drug": "Tepotinib (Tepmetko)",
"disease": "Metastatic Non-Small Cell Lung Cancer",
"line": "Any line",
"setting": "MET exon 14 skipping mutations (~3% of NSCLC)",
"last_updated": "2025-01-17",
"updated_by": "EMD Serono Competitive Intelligence Tool"
},
"direct_competitors": [
{
"drug": "Capmatinib",
"company": "Novartis",
"moa": "Type Ib MET TKI",
"trials": "GEOMETRY mono-1 (ORR 68% 1L, 41% 2L+; FDA approved 2020)",
"threat_level": "HIGH",
"rationale": "First FDA-approved MET inhibitor for METex14, similar efficacy profile",
"keywords": ["capmatinib", "tabrecta", "GEOMETRY", "INC280", "INC-280", "METex14"]
},
{
"drug": "Savolitinib",
"company": "HUTCHMED/AstraZeneca",
"moa": "Type Ib MET TKI",
"trials": "Phase IIIb China (ORR 62% 1L, 40% 2L+; China approved 2021)",
"threat_level": "MEDIUM",
"rationale": "Approved in China only, shows similar efficacy to tepotinib",
"keywords": ["savolitinib", "orpathys", "AZD6094", "AZD-6094", "HMPL-504", "HMPL504", "volitinib"]
},
{
"drug": "Crizotinib",
"company": "Pfizer",
"moa": "Type Ia multi-kinase inhibitor (MET/ALK/ROS1)",
"trials": "PROFILE 1001 (ORR 32% in METex14)",
"threat_level": "LOW",
"rationale": "Off-label use, less selective, inferior CNS penetration",
"keywords": ["crizotinib", "xalkori", "PROFILE", "PF-02341066"]
}
],
"emerging_threats": [
{
"drug": "Elzovantinib (TPX-0022)",
"company": "Bristol Myers Squibb",
"moa": "Type I MET/SRC/CSF1R inhibitor",
"phase": "Phase 1/2 (SHIELD-1)",
"biomarker": "MET alterations including ex14",
"threat_level": "MEDIUM",
"keywords": ["elzovantinib", "TPX-0022", "SHIELD-1", "turning point"]
},
{
"drug": "Amivantamab",
"company": "Johnson & Johnson",
"moa": "Bispecific EGFR/MET antibody",
"phase": "Phase 1 (CHRYSALIS)",
"biomarker": "METex14 or MET amplification",
"threat_level": "MEDIUM",
"keywords": ["amivantamab", "rybrevant", "JNJ-61186372", "CHRYSALIS"]
},
{
"drug": "Cabozantinib",
"company": "Exelixis",
"moa": "Type II multi-targeted TKI",
"phase": "Phase 2 (CAPTURE for resistance)",
"biomarker": "MET D1228/Y1230 resistance mutations",
"threat_level": "LOW",
"keywords": ["cabozantinib", "cabometyx", "cometriq", "XL184"]
},
{
"drug": "Foretinib",
"company": "GlaxoSmithKline",
"moa": "Type II MET/VEGFR inhibitor",
"phase": "Preclinical/Phase 1",
"biomarker": "MET resistance mutations",
"threat_level": "LOW",
"keywords": ["foretinib", "GSK1363089", "GSK-1363089", "XL880"]
},
{
"drug": "Merestinib",
"company": "Eli Lilly",
"moa": "Type II MET inhibitor",
"phase": "Phase 2",
"biomarker": "MET alterations",
"threat_level": "LOW",
"keywords": ["merestinib", "LY2801653", "LY-2801653"]
}
],
"key_biomarkers": [
{
"biomarker": "MET exon 14 skipping",
"clinical_utility": "Primary driver mutation, diagnostic for MET TKI treatment",
"prevalence": "3-4% of NSCLC, higher in elderly/non-smokers",
"keywords": ["METex14", "MET delta ex14", "exon 14 skipping", "splice site"]
},
{
"biomarker": "MET amplification",
"clinical_utility": "Primary driver or resistance mechanism, GCN â‰¥10 predicts response",
"prevalence": "1-5% primary, up to 20% post-EGFR TKI",
"keywords": ["MET amplification", "gene copy number", "GCN", "FISH", "NGS"]
},
{
"biomarker": "Liquid biopsy ctDNA",
"clinical_utility": "Non-invasive detection and monitoring of METex14",
"prevalence": "~70% concordance with tissue",
"keywords": ["ctDNA", "liquid biopsy", "Guardant360", "FoundationOne Liquid"]
}
],
"resistance_mechanisms": [
{
"mechanism": "MET D1228 mutations",
"frequency": "~15-20% of acquired resistance",
"treatment_options": "Type II inhibitors (cabozantinib, foretinib)",
"keywords": ["D1228", "D1228H", "D1228N", "D1228V", "activation loop"]
},
{
"mechanism": "MET Y1230 mutations",
"frequency": "~15-20% of acquired resistance",
"treatment_options": "Type II inhibitors, some respond to savolitinib",
"keywords": ["Y1230", "Y1230C", "Y1230H", "Y1230N", "kinase domain"]
},
{
"mechanism": "KRAS/BRAF amplification",
"frequency": "~20-30% off-target resistance",
"treatment_options": "Combination therapy, clinical trials",
"keywords": ["KRAS", "BRAF", "bypass pathway", "off-target"]
},
{
"mechanism": "PI3K/AKT activation",
"frequency": "~10-15%",
"treatment_options": "PI3K inhibitors in combination",
"keywords": ["PI3K", "AKT", "PIK3CA", "downstream signaling"]
},
{
"mechanism": "MET gene amplification",
"frequency": "~5-10%",
"treatment_options": "Higher dose MET TKI or combination",
"keywords": ["MET amplification", "copy number gain", "dose escalation"]
}
],
"paradigm_shifts": [
{
"old": "Chemotherapy for all METex14 patients",
"new": "MET TKIs as preferred first-line therapy",
"impact": "Tepotinib competes with capmatinib for market share",
"year": "2020-2021"
},
{
"old": "Tissue biopsy only for METex14 detection",
"new": "Liquid biopsy as complementary/alternative diagnostic",
"impact": "Expanded patient identification for tepotinib",
"year": "2020-2025"
},
{
"old": "Single MET TKI until progression",
"new": "Sequential therapy with different MET TKI types",
"impact": "Tepotinib positioned in treatment sequence based on resistance profile",
"year": "2022-2025"
},
{
"old": "MET inhibitors only for METex14",
"new": "Exploration in MET amplification and other alterations",
"impact": "Potential market expansion for tepotinib",
"year": "2023-ongoing"
}
],
"exclusions": {
"settings": ["EGFR-mutant NSCLC", "ALK-positive NSCLC", "KRAS-mutant NSCLC", "MET amplification without METex14"],
"rationale": "Different competitive sets, not relevant to METex14 skipping"
}
}